RxDoctor Payments Data

Roberta Lieber

Family · White Plains, NYNPI 1851716294

Payments from drug & device makers

$498in general payments, 2019–2025

Across 15 payments — averaging $33.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$125
  • AbbVie$125
  • GSK$57
  • Regeneron Healthcare Solutions, Inc.$41
  • AstraZeneca$36
  • Philips North America LLC$30
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$498 in reported general payments places this provider in the 60th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$72,008
Medicare patients
326
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$43,052
EliquisApixaban16$26,454
Rosuvastatin Calcium180$2,263
Dipyridamole13$1,929
Amlodipine Besylate174$1,613
Atorvastatin Calcium115$1,224
Potassium Chloride26$1,118
Nebivolol Hcl13$1,044
Losartan Potassium128$1,041
Albuterol Sulfate HfaAlbuterol Sulfate35$993
Metoprolol Succinate73$922
Olmesartan Medoxomil29$870
Pantoprazole Sodium50$703
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip27$672
Levetiracetam ErLevetiracetam13$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$26,45416 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$65966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,883 family providers in New York.

Other family in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →